(RMD) ResMed - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7611521078

RMD: Devices, Software, Therapies, Diagnostics, Solutions, Equipment

ResMed Inc., a leader in the sleep and respiratory care industry, is at the forefront of the health tech revolution. As a prominent figure in this space, ResMed is capitalizing on the growing awareness of sleep disorders and the increasing demand for remote patient monitoring solutions, especially in the post-pandemic era.

The companys product portfolio is a blend of hardware and software, designed to cater to both clinical and operational needs. On the hardware side, ResMed offers devices like ApneaLink Air and NightOwl, which provide comprehensive diagnostic data essential for accurate patient assessments. These tools are complemented by software solutions such as AirView and myAir, which enhance patient engagement and streamline care management, reflecting ResMeds commitment to integrating technology into healthcare delivery.

ResMeds out-of-hospital software solutions, including Brightree and MatrixCare, are pivotal for managing operations in home healthcare and related services. These platforms not only improve efficiency but also position ResMed as a comprehensive solution provider in the healthcare sector.

The companys distribution strategy, combining direct sales and a robust network of distributors, ensures their products reach sleep clinics, home healthcare providers, and hospitals effectively. This strategic approach underscores ResMeds ability to meet market demands comprehensively.

Financially, ResMed boasts a market cap of over $34 billion, with valuation multiples indicating a company poised for growth. Their focus on expanding software capabilities through strategic acquisitions, coupled with advancements in data analytics and AI, underscores their commitment to innovation and operational efficiency.

In summary, ResMeds diversified product range, strong distribution network, and strategic acquisitions make it a compelling investment in the growing healthcare technology industry. Their comprehensive solutions position them as a leader, aligning with the trends driving the future of healthcare.

Additional Sources for RMD Stock

RMD Stock Overview

Market Cap in USD 30,133m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Health Care Equipment
IPO / Inception 1995-06-02

RMD Stock Ratings

Growth Rating 25.1
Fundamental 91.9
Dividend Rating 55.6
Rel. Strength 24.3
Analysts 3.72/5
Fair Price Momentum 201.69 USD
Fair Price DCF 207.77 USD

RMD Dividends

Dividend Yield 12m 0.94%
Yield on Cost 5y 1.31%
Annual Growth 5y 5.30%
Payout Consistency 100.0%

RMD Growth Ratios

Growth Correlation 3m -94.1%
Growth Correlation 12m 44.5%
Growth Correlation 5y 18.9%
CAGR 5y 6.21%
CAGR/Max DD 5y 0.11
Sharpe Ratio 12m 0.40
Alpha 14.90
Beta 0.737
Volatility 31.00%
Current Volume 1109.6k
Average Volume 20d 1098.1k
What is the price of RMD stocks?
As of April 18, 2025, the stock is trading at USD 212.91 with a total of 1,109,562 shares traded.
Over the past week, the price has changed by +1.12%, over one month by -5.26%, over three months by -11.01% and over the past year by +23.59%.
Is ResMed a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, ResMed (NYSE:RMD) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 91.88 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RMD as of April 2025 is 201.69. This means that RMD is currently overvalued and has a potential downside of -5.27%.
Is RMD a buy, sell or hold?
ResMed has received a consensus analysts rating of 3.72. Therefor, it is recommend to hold RMD.
  • Strong Buy: 6
  • Buy: 3
  • Hold: 8
  • Sell: 0
  • Strong Sell: 1
What are the forecast for RMD stock price target?
According to ValueRays Forecast Model, RMD ResMed will be worth about 221.6 in April 2026. The stock is currently trading at 212.91. This means that the stock has a potential upside of +4.06%.
Issuer Forecast Upside
Wallstreet Target Price 269.4 26.5%
Analysts Target Price 256 20.2%
ValueRay Target Price 221.6 4.1%